Merck KGaA announces the completion of the acquisition of Sigma-Aldrich, a St. Louis-based life-sciences and technology company.
Merck KGaA, Darmstadt, Germany announced on Nov. 18, 2015, the completion of their acquisition of Sigma-Aldrich, a St. Louis-based life-science and technology company, according to a press release.
The $17-billion acquisition follows last week’s approval from the European Commission, the final antitrust condition required to close the Sigma-Aldrich transaction.
The acquisition boosts Merck KGaA to around 50,000 employees in 67 countries worldwide.
In 2014, Merck KGaA’s life sciences division grossed a total of €4.6 billion (approximately $4.89 billion) in sales. With the addition of Sigma-Aldrich, the company expects a total gross of between €12.6 billion (approximately $13.4 billion) and €12.8 billion (approximately $13.61 billion) for 2015.
Merck KGaA announced the acquisition of Sigma-Aldrich in a September 2014 press release, saying this decision would allow them to increase their presence in the North American and Asian markets.
According to the company, the acquisition merged Merck KGaA’s existing life-sciences division, EMD Millipore, with Sigma-Aldrich, now MilliporeSigma.
Merck KGaA has made nearly €38 billion (approximately $40.4 billion) in acquisitions and divestments in the past 10 years, expanding their business in the areas of science, technology, healthcare, and life science.
Source: Merck KGaA
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Entering New Domains for 3D Printing of Drug Products
April 6th 20253D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.